Risk of tumour recurrence following curative treatment of hepatocellular carcinoma.

IF 1.7 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Scandinavian Journal of Gastroenterology Pub Date : 2025-09-29 DOI:10.1080/00365521.2025.2565334

Bonnie Bengtsson, Gustaf Pak, Juan Vaz, Linnea Widman, Hannes Hagström

{"title":"Risk of tumour recurrence following curative treatment of hepatocellular carcinoma.","authors":"Bonnie Bengtsson, Gustaf Pak, Juan Vaz, Linnea Widman, Hannes Hagström","doi":"10.1080/00365521.2025.2565334","DOIUrl":null,"url":null,"abstract":"Objectives: Tumour recurrence remains a major obstacle to long-term survival following curative treatment for hepatocellular carcinoma (HCC). This cohort study aimed to identify clinical and tumour-related factors associated with HCC recurrence.Methods: A total of 346 patients treated with curative intent at Karolinska University Hospital between 2010 and 2017 were analysed. Patients were stratified by treatment modality and recurrence status.Results: Resection (adjusted hazard ratio [aHR] = 6.0, 95%CI = 2.5-14.5) and ablation (aHR = 10.3, 95%CI = 4.5-23.7) were independently associated with higher recurrence compared to liver transplantation. Alpha-fetoprotein (AFP) levels ≥100 µg/L (aHR = 3.1, 95%CI = 2.0-4.7) and active smoking at baseline (aHR = 1.7, 95%CI = 1.1-2.6) were significantly associated with recurrence.Conclusion: These findings highlight the relevance of AFP in recurrence prediction and surveillance planning and points out that smoking history can be of importance although this needs to be further validated.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-4"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00365521.2025.2565334","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Tumour recurrence remains a major obstacle to long-term survival following curative treatment for hepatocellular carcinoma (HCC). This cohort study aimed to identify clinical and tumour-related factors associated with HCC recurrence.

Methods: A total of 346 patients treated with curative intent at Karolinska University Hospital between 2010 and 2017 were analysed. Patients were stratified by treatment modality and recurrence status.

Results: Resection (adjusted hazard ratio [aHR] = 6.0, 95%CI = 2.5-14.5) and ablation (aHR = 10.3, 95%CI = 4.5-23.7) were independently associated with higher recurrence compared to liver transplantation. Alpha-fetoprotein (AFP) levels ≥100 µg/L (aHR = 3.1, 95%CI = 2.0-4.7) and active smoking at baseline (aHR = 1.7, 95%CI = 1.1-2.6) were significantly associated with recurrence.

Conclusion: These findings highlight the relevance of AFP in recurrence prediction and surveillance planning and points out that smoking history can be of importance although this needs to be further validated.

查看原文本刊更多论文

肝癌根治性治疗后肿瘤复发的风险。

目的：肿瘤复发仍然是肝细胞癌（HCC）根治性治疗后长期生存的主要障碍。本队列研究旨在确定与HCC复发相关的临床和肿瘤相关因素。方法：对2010 - 2017年在卡罗林斯卡大学医院就诊的346例有治愈意向的患者进行分析。根据治疗方式和复发情况对患者进行分层。结果：与肝移植相比，切除（校正危险比[aHR] = 6.0, 95%CI = 2.5-14.5）和消融（aHR = 10.3, 95%CI = 4.5-23.7）与更高的复发率独立相关。甲胎蛋白（AFP）水平≥100µg/L （aHR = 3.1, 95%CI = 2.0-4.7）和基线时积极吸烟（aHR = 1.7, 95%CI = 1.1-2.6）与复发显著相关。结论：这些发现强调了AFP与复发预测和监测计划的相关性，并指出吸烟史可能是重要的，尽管这需要进一步验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Scandinavian Journal of Gastroenterology 医学-胃肠肝病学

CiteScore

3.40

自引率

5.30%

发文量

222

审稿时长

3-8 weeks

期刊介绍： The Scandinavian Journal of Gastroenterology is one of the most important journals for international medical research in gastroenterology and hepatology with international contributors, Editorial Board, and distribution